Ind-Swift Limited
Ind-Swift Limited (INDSWFTLTD.BO) Stock Competitors & Peer Comparison
See (INDSWFTLTD.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| INDSWFTLTD.BO | ₹15.70 | +4.81% | 850.4M | 0.30 | ₹52.33 | N/A |
| SUNPHARMA.BO | ₹1,728.45 | -3.74% | 4.2T | 38.62 | ₹45.50 | +0.88% |
| SUNPHARMA.NS | ₹1,728.50 | -3.63% | 4.2T | 38.57 | ₹45.56 | +0.88% |
| DIVISLAB.NS | ₹5,906.50 | -1.52% | 1.6T | 63.69 | ₹93.37 | +0.50% |
| DIVISLAB.BO | ₹5,906.95 | -1.49% | 1.6T | 63.69 | ₹93.36 | +0.50% |
| TORNTPHARM.BO | ₹4,108.55 | -3.70% | 1.4T | 66.73 | ₹63.25 | +0.76% |
| TORNTPHARM.NS | ₹4,111.30 | -3.62% | 1.4T | 62.89 | ₹67.10 | +0.76% |
| LUPIN.NS | ₹2,274.90 | -2.57% | 1.1T | 22.84 | ₹101.33 | +0.52% |
| LUPIN.BO | ₹2,273.60 | -2.63% | 1.1T | 24.51 | ₹94.37 | +0.52% |
| DRREDDY.NS | ₹1,209.60 | -5.63% | 1T | 18.47 | ₹67.93 | +0.64% |
Stock Comparison
INDSWFTLTD.BO vs SUNPHARMA.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, SUNPHARMA.BO has a market cap of 4.2T. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while SUNPHARMA.BO trades at ₹1,728.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas SUNPHARMA.BO's P/E ratio is 38.62. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check SUNPHARMA.BO's competition here
INDSWFTLTD.BO vs SUNPHARMA.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, SUNPHARMA.NS has a market cap of 4.2T. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while SUNPHARMA.NS trades at ₹1,728.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas SUNPHARMA.NS's P/E ratio is 38.57. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check SUNPHARMA.NS's competition here
INDSWFTLTD.BO vs DIVISLAB.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, DIVISLAB.NS has a market cap of 1.6T. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while DIVISLAB.NS trades at ₹5,906.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas DIVISLAB.NS's P/E ratio is 63.69. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check DIVISLAB.NS's competition here
INDSWFTLTD.BO vs DIVISLAB.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, DIVISLAB.BO has a market cap of 1.6T. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while DIVISLAB.BO trades at ₹5,906.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas DIVISLAB.BO's P/E ratio is 63.69. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check DIVISLAB.BO's competition here
INDSWFTLTD.BO vs TORNTPHARM.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, TORNTPHARM.BO has a market cap of 1.4T. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while TORNTPHARM.BO trades at ₹4,108.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas TORNTPHARM.BO's P/E ratio is 66.73. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to TORNTPHARM.BO's ROE of +0.29%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check TORNTPHARM.BO's competition here
INDSWFTLTD.BO vs TORNTPHARM.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, TORNTPHARM.NS has a market cap of 1.4T. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while TORNTPHARM.NS trades at ₹4,111.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas TORNTPHARM.NS's P/E ratio is 62.89. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to TORNTPHARM.NS's ROE of +0.29%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check TORNTPHARM.NS's competition here
INDSWFTLTD.BO vs LUPIN.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while LUPIN.NS trades at ₹2,274.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas LUPIN.NS's P/E ratio is 22.84. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check LUPIN.NS's competition here
INDSWFTLTD.BO vs LUPIN.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while LUPIN.BO trades at ₹2,273.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas LUPIN.BO's P/E ratio is 24.51. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check LUPIN.BO's competition here
INDSWFTLTD.BO vs DRREDDY.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, DRREDDY.NS has a market cap of 1T. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while DRREDDY.NS trades at ₹1,209.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas DRREDDY.NS's P/E ratio is 18.47. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to DRREDDY.NS's ROE of +0.16%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check DRREDDY.NS's competition here
INDSWFTLTD.BO vs DRREDDY.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, DRREDDY.BO has a market cap of 1T. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while DRREDDY.BO trades at ₹1,209.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas DRREDDY.BO's P/E ratio is 18.49. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to DRREDDY.BO's ROE of +0.16%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check DRREDDY.BO's competition here
INDSWFTLTD.BO vs ZYDUSLIFE.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, ZYDUSLIFE.BO has a market cap of 876.6B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while ZYDUSLIFE.BO trades at ₹863.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas ZYDUSLIFE.BO's P/E ratio is 17.76. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check ZYDUSLIFE.BO's competition here
INDSWFTLTD.BO vs ZYDUSLIFE.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, ZYDUSLIFE.NS has a market cap of 876.6B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while ZYDUSLIFE.NS trades at ₹863.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas ZYDUSLIFE.NS's P/E ratio is 17.76. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check ZYDUSLIFE.NS's competition here
INDSWFTLTD.BO vs MANKIND.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, MANKIND.BO has a market cap of 828B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while MANKIND.BO trades at ₹2,001.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas MANKIND.BO's P/E ratio is 46.51. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to MANKIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check MANKIND.BO's competition here
INDSWFTLTD.BO vs MANKIND.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, MANKIND.NS has a market cap of 828B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while MANKIND.NS trades at ₹2,001.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas MANKIND.NS's P/E ratio is 46.52. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to MANKIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check MANKIND.NS's competition here
INDSWFTLTD.BO vs AUROPHARMA.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, AUROPHARMA.NS has a market cap of 757.6B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while AUROPHARMA.NS trades at ₹1,342.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas AUROPHARMA.NS's P/E ratio is 21.72. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to AUROPHARMA.NS's ROE of +0.11%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to AUROPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check AUROPHARMA.NS's competition here
INDSWFTLTD.BO vs AUROPHARMA.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, AUROPHARMA.BO has a market cap of 756.9B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while AUROPHARMA.BO trades at ₹1,342.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas AUROPHARMA.BO's P/E ratio is 22.13. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to AUROPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check AUROPHARMA.BO's competition here
INDSWFTLTD.BO vs ALKEM.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, ALKEM.BO has a market cap of 634.1B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while ALKEM.BO trades at ₹5,240.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas ALKEM.BO's P/E ratio is 26.75. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check ALKEM.BO's competition here
INDSWFTLTD.BO vs ALKEM.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, ALKEM.NS has a market cap of 633.6B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while ALKEM.NS trades at ₹5,244.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas ALKEM.NS's P/E ratio is 26.72. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check ALKEM.NS's competition here
INDSWFTLTD.BO vs GLENMARK.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, GLENMARK.BO has a market cap of 602B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while GLENMARK.BO trades at ₹2,100.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas GLENMARK.BO's P/E ratio is 56.48. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to GLENMARK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check GLENMARK.BO's competition here
INDSWFTLTD.BO vs GLENMARK.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, GLENMARK.NS has a market cap of 601.6B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while GLENMARK.NS trades at ₹2,101.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas GLENMARK.NS's P/E ratio is 56.44. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to GLENMARK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check GLENMARK.NS's competition here
INDSWFTLTD.BO vs LAURUSLABS.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, LAURUSLABS.NS has a market cap of 535.9B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while LAURUSLABS.NS trades at ₹1,038.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas LAURUSLABS.NS's P/E ratio is 63.47. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to LAURUSLABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check LAURUSLABS.NS's competition here
INDSWFTLTD.BO vs LAURUSLABS.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, LAURUSLABS.BO has a market cap of 535.5B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while LAURUSLABS.BO trades at ₹1,039.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas LAURUSLABS.BO's P/E ratio is 63.42. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to LAURUSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check LAURUSLABS.BO's competition here
INDSWFTLTD.BO vs SUVENPHAR.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while SUVENPHAR.NS trades at ₹1,078.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to SUVENPHAR.NS's ROE of +0.13%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to SUVENPHAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check SUVENPHAR.NS's competition here
INDSWFTLTD.BO vs SUVENPHAR.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to SUVENPHAR.BO's ROE of +0.09%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to SUVENPHAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check SUVENPHAR.BO's competition here
INDSWFTLTD.BO vs IPCALAB.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, IPCALAB.BO has a market cap of 406.7B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while IPCALAB.BO trades at ₹1,510.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas IPCALAB.BO's P/E ratio is 44.64. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to IPCALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check IPCALAB.BO's competition here
INDSWFTLTD.BO vs IPCALAB.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, IPCALAB.NS has a market cap of 406.2B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while IPCALAB.NS trades at ₹1,508.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas IPCALAB.NS's P/E ratio is 44.64. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to IPCALAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check IPCALAB.NS's competition here
INDSWFTLTD.BO vs AJANTPHARM.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, AJANTPHARM.NS has a market cap of 350.5B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while AJANTPHARM.NS trades at ₹2,816.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas AJANTPHARM.NS's P/E ratio is 34.48. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check AJANTPHARM.NS's competition here
INDSWFTLTD.BO vs AJANTPHARM.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, AJANTPHARM.BO has a market cap of 350.3B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while AJANTPHARM.BO trades at ₹2,821.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas AJANTPHARM.BO's P/E ratio is 34.56. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check AJANTPHARM.BO's competition here
INDSWFTLTD.BO vs JBCHEPHARM.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, JBCHEPHARM.NS has a market cap of 331.5B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while JBCHEPHARM.NS trades at ₹2,008.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas JBCHEPHARM.NS's P/E ratio is 43.45. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to JBCHEPHARM.NS's ROE of +0.22%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check JBCHEPHARM.NS's competition here
INDSWFTLTD.BO vs JBCHEPHARM.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, JBCHEPHARM.BO has a market cap of 331.3B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while JBCHEPHARM.BO trades at ₹2,010.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas JBCHEPHARM.BO's P/E ratio is 43.41. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to JBCHEPHARM.BO's ROE of +0.22%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to JBCHEPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check JBCHEPHARM.BO's competition here
INDSWFTLTD.BO vs EMCURE.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, EMCURE.NS has a market cap of 302.5B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while EMCURE.NS trades at ₹1,590.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas EMCURE.NS's P/E ratio is 34.72. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to EMCURE.NS's ROE of +0.19%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to EMCURE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check EMCURE.NS's competition here
INDSWFTLTD.BO vs PEL.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to PEL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check PEL.NS's competition here
INDSWFTLTD.BO vs ASTRAZEN.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, ASTRAZEN.NS has a market cap of 194.1B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while ASTRAZEN.NS trades at ₹7,852.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas ASTRAZEN.NS's P/E ratio is 96.95. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to ASTRAZEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check ASTRAZEN.NS's competition here
INDSWFTLTD.BO vs ASTRAZEN.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, ASTRAZEN.BO has a market cap of 194B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while ASTRAZEN.BO trades at ₹7,852.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas ASTRAZEN.BO's P/E ratio is 96.68. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check ASTRAZEN.BO's competition here
INDSWFTLTD.BO vs WOCKPHARMA.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, WOCKPHARMA.BO has a market cap of 191.3B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while WOCKPHARMA.BO trades at ₹1,267.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas WOCKPHARMA.BO's P/E ratio is 912.60. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to WOCKPHARMA.BO's ROE of +0.01%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to WOCKPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check WOCKPHARMA.BO's competition here
INDSWFTLTD.BO vs WOCKPHARMA.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, WOCKPHARMA.NS has a market cap of 191B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while WOCKPHARMA.NS trades at ₹1,267.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas WOCKPHARMA.NS's P/E ratio is 911.40. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to WOCKPHARMA.NS's ROE of +0.01%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to WOCKPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check WOCKPHARMA.NS's competition here
INDSWFTLTD.BO vs PPLPHARMA.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, PPLPHARMA.BO has a market cap of 180.6B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while PPLPHARMA.BO trades at ₹142.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas PPLPHARMA.BO's P/E ratio is -110.93. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to PPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to PPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check PPLPHARMA.BO's competition here
INDSWFTLTD.BO vs ERIS.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, ERIS.BO has a market cap of 179.9B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while ERIS.BO trades at ₹1,311.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas ERIS.BO's P/E ratio is 41.15. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to ERIS.BO's ROE of +0.14%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check ERIS.BO's competition here
INDSWFTLTD.BO vs ERIS.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, ERIS.NS has a market cap of 179.7B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while ERIS.NS trades at ₹1,310.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas ERIS.NS's P/E ratio is 41.17. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to ERIS.NS's ROE of +0.14%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check ERIS.NS's competition here
INDSWFTLTD.BO vs NATCOPHARM.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, NATCOPHARM.BO has a market cap of 174.6B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while NATCOPHARM.BO trades at ₹1,001.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas NATCOPHARM.BO's P/E ratio is 11.35. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to NATCOPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check NATCOPHARM.BO's competition here
INDSWFTLTD.BO vs NATCOPHARM.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, NATCOPHARM.NS has a market cap of 174.5B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while NATCOPHARM.NS trades at ₹1,001.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas NATCOPHARM.NS's P/E ratio is 11.21. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to NATCOPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check NATCOPHARM.NS's competition here
INDSWFTLTD.BO vs NEULANDLAB.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, NEULANDLAB.NS has a market cap of 154.3B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while NEULANDLAB.NS trades at ₹12,613.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas NEULANDLAB.NS's P/E ratio is 86.21. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to NEULANDLAB.NS's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to NEULANDLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check NEULANDLAB.NS's competition here
INDSWFTLTD.BO vs NEULANDLAB.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, NEULANDLAB.BO has a market cap of 154.1B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while NEULANDLAB.BO trades at ₹12,604.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas NEULANDLAB.BO's P/E ratio is 86.20. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to NEULANDLAB.BO's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to NEULANDLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check NEULANDLAB.BO's competition here
INDSWFTLTD.BO vs GRANULES.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, GRANULES.BO has a market cap of 150.7B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while GRANULES.BO trades at ₹628.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas GRANULES.BO's P/E ratio is 27.62. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to GRANULES.BO's ROE of +0.15%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to GRANULES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check GRANULES.BO's competition here
INDSWFTLTD.BO vs GRANULES.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, GRANULES.NS has a market cap of 150.6B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while GRANULES.NS trades at ₹628.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas GRANULES.NS's P/E ratio is 27.60. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to GRANULES.NS's ROE of +0.15%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to GRANULES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check GRANULES.NS's competition here
INDSWFTLTD.BO vs GLS.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to GLS.NS's ROE of +0.09%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to GLS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check GLS.NS's competition here
INDSWFTLTD.BO vs GLS.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to GLS.BO's ROE of +0.19%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to GLS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check GLS.BO's competition here
INDSWFTLTD.BO vs APLLTD.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, APLLTD.NS has a market cap of 130.4B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while APLLTD.NS trades at ₹677.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas APLLTD.NS's P/E ratio is 20.71. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to APLLTD.NS's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check APLLTD.NS's competition here
INDSWFTLTD.BO vs APLLTD.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, APLLTD.BO has a market cap of 130.1B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while APLLTD.BO trades at ₹676.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas APLLTD.BO's P/E ratio is 20.66. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to APLLTD.BO's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to APLLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check APLLTD.BO's competition here
INDSWFTLTD.BO vs JUBLPHARMA.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, JUBLPHARMA.NS has a market cap of 129.3B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while JUBLPHARMA.NS trades at ₹816.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas JUBLPHARMA.NS's P/E ratio is 29.94. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to JUBLPHARMA.NS's ROE of +0.07%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to JUBLPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check JUBLPHARMA.NS's competition here
INDSWFTLTD.BO vs JUBLPHARMA.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, JUBLPHARMA.BO has a market cap of 129.3B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while JUBLPHARMA.BO trades at ₹816.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas JUBLPHARMA.BO's P/E ratio is 29.94. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to JUBLPHARMA.BO's ROE of +0.07%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to JUBLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check JUBLPHARMA.BO's competition here
INDSWFTLTD.BO vs ALIVUS.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, ALIVUS.BO has a market cap of 119.6B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while ALIVUS.BO trades at ₹984.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas ALIVUS.BO's P/E ratio is 22.03. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to ALIVUS.BO's ROE of +0.09%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to ALIVUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check ALIVUS.BO's competition here
INDSWFTLTD.BO vs ALIVUS.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, ALIVUS.NS has a market cap of 119.4B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while ALIVUS.NS trades at ₹984.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas ALIVUS.NS's P/E ratio is 21.98. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to ALIVUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check ALIVUS.NS's competition here
INDSWFTLTD.BO vs COHANCE.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, COHANCE.BO has a market cap of 115.5B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while COHANCE.BO trades at ₹311.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas COHANCE.BO's P/E ratio is 59.78. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to COHANCE.BO's ROE of +0.09%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to COHANCE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check COHANCE.BO's competition here
INDSWFTLTD.BO vs COHANCE.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, COHANCE.NS has a market cap of 115.3B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while COHANCE.NS trades at ₹311.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas COHANCE.NS's P/E ratio is 59.58. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to COHANCE.NS's ROE of +0.09%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to COHANCE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check COHANCE.NS's competition here
INDSWFTLTD.BO vs CAPLIPOINT.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, CAPLIPOINT.BO has a market cap of 114.4B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while CAPLIPOINT.BO trades at ₹1,573.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas CAPLIPOINT.BO's P/E ratio is 18.69. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to CAPLIPOINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check CAPLIPOINT.BO's competition here
INDSWFTLTD.BO vs CAPLIPOINT.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, CAPLIPOINT.NS has a market cap of 114.4B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while CAPLIPOINT.NS trades at ₹1,570.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas CAPLIPOINT.NS's P/E ratio is 18.69. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to CAPLIPOINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check CAPLIPOINT.NS's competition here
INDSWFTLTD.BO vs CAPPL.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to CAPPL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check CAPPL.BO's competition here
INDSWFTLTD.BO vs STAR.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, STAR.BO has a market cap of 86.4B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while STAR.BO trades at ₹965.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas STAR.BO's P/E ratio is 16.89. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to STAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check STAR.BO's competition here
INDSWFTLTD.BO vs STAR.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, STAR.NS has a market cap of 86.4B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while STAR.NS trades at ₹963.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas STAR.NS's P/E ratio is 16.89. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to STAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check STAR.NS's competition here
INDSWFTLTD.BO vs VIYASH.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, VIYASH.NS has a market cap of 79.8B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while VIYASH.NS trades at ₹192.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas VIYASH.NS's P/E ratio is 70.32. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to VIYASH.NS's ROE of +0.10%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to VIYASH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check VIYASH.NS's competition here
INDSWFTLTD.BO vs PGHL.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, PGHL.NS has a market cap of 79.7B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while PGHL.NS trades at ₹4,809.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas PGHL.NS's P/E ratio is 33.72. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check PGHL.NS's competition here
INDSWFTLTD.BO vs PGHL.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, PGHL.BO has a market cap of 79.6B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while PGHL.BO trades at ₹4,807.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas PGHL.BO's P/E ratio is 33.70. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check PGHL.BO's competition here
INDSWFTLTD.BO vs AKUMS.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, AKUMS.NS has a market cap of 71.4B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while AKUMS.NS trades at ₹496.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas AKUMS.NS's P/E ratio is 22.32. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to AKUMS.NS's ROE of +0.10%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to AKUMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check AKUMS.NS's competition here
INDSWFTLTD.BO vs SHILPAMED.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, SHILPAMED.NS has a market cap of 68.2B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while SHILPAMED.NS trades at ₹374.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas SHILPAMED.NS's P/E ratio is 30.90. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to SHILPAMED.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check SHILPAMED.NS's competition here
INDSWFTLTD.BO vs AARTIPHARM.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, AARTIPHARM.NS has a market cap of 53.7B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while AARTIPHARM.NS trades at ₹635.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas AARTIPHARM.NS's P/E ratio is 25.13. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to AARTIPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check AARTIPHARM.NS's competition here
INDSWFTLTD.BO vs AARTIPHARM.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, AARTIPHARM.BO has a market cap of 53.4B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while AARTIPHARM.BO trades at ₹638.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas AARTIPHARM.BO's P/E ratio is 25.00. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to AARTIPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check AARTIPHARM.BO's competition here
INDSWFTLTD.BO vs FDC.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, FDC.BO has a market cap of 52.3B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while FDC.BO trades at ₹328.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas FDC.BO's P/E ratio is 24.17. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to FDC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check FDC.BO's competition here
INDSWFTLTD.BO vs FDC.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, FDC.NS has a market cap of 52.3B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while FDC.NS trades at ₹328.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas FDC.NS's P/E ratio is 24.16. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to FDC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check FDC.NS's competition here
INDSWFTLTD.BO vs SEQUENT.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to SEQUENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check SEQUENT.NS's competition here
INDSWFTLTD.BO vs SEQUENT.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to SEQUENT.BO's ROE of +0.10%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to SEQUENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check SEQUENT.BO's competition here
INDSWFTLTD.BO vs INNOVACAP.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, INNOVACAP.NS has a market cap of 39.5B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while INNOVACAP.NS trades at ₹703.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas INNOVACAP.NS's P/E ratio is 29.79. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to INNOVACAP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check INNOVACAP.NS's competition here
INDSWFTLTD.BO vs SPARC.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, SPARC.NS has a market cap of 37.3B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while SPARC.NS trades at ₹120.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas SPARC.NS's P/E ratio is -13.93. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to SPARC.NS's ROE of +1.25%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to SPARC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check SPARC.NS's competition here
INDSWFTLTD.BO vs SPARC.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, SPARC.BO has a market cap of 37.2B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while SPARC.BO trades at ₹120.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas SPARC.BO's P/E ratio is -13.89. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to SPARC.BO's ROE of +1.25%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to SPARC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check SPARC.BO's competition here
INDSWFTLTD.BO vs SHILPAMED.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, SHILPAMED.BO has a market cap of 34.1B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while SHILPAMED.BO trades at ₹374.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas SHILPAMED.BO's P/E ratio is 30.85. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to SHILPAMED.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check SHILPAMED.BO's competition here
INDSWFTLTD.BO vs SUVEN.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, SUVEN.BO has a market cap of 30.8B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while SUVEN.BO trades at ₹147.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas SUVEN.BO's P/E ratio is -10.79. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to SUVEN.BO's ROE of -1.58%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to SUVEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check SUVEN.BO's competition here
INDSWFTLTD.BO vs RPGLIFE.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, RPGLIFE.NS has a market cap of 30.7B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while RPGLIFE.NS trades at ₹1,877.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas RPGLIFE.NS's P/E ratio is 15.16. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to RPGLIFE.NS's ROE of +0.41%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to RPGLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check RPGLIFE.NS's competition here
INDSWFTLTD.BO vs RPGLIFE.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, RPGLIFE.BO has a market cap of 30.6B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while RPGLIFE.BO trades at ₹1,878.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas RPGLIFE.BO's P/E ratio is 15.11. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to RPGLIFE.BO's ROE of +0.41%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to RPGLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check RPGLIFE.BO's competition here
INDSWFTLTD.BO vs SUVEN.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, SUVEN.NS has a market cap of 30.5B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while SUVEN.NS trades at ₹147.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas SUVEN.NS's P/E ratio is -10.70. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to SUVEN.NS's ROE of -1.58%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to SUVEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check SUVEN.NS's competition here
INDSWFTLTD.BO vs AARTIDRUGS.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, AARTIDRUGS.NS has a market cap of 29.2B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while AARTIDRUGS.NS trades at ₹346.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas AARTIDRUGS.NS's P/E ratio is 14.47. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to AARTIDRUGS.NS's ROE of +0.15%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to AARTIDRUGS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check AARTIDRUGS.NS's competition here
INDSWFTLTD.BO vs AARTIDRUGS.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, AARTIDRUGS.BO has a market cap of 29.2B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while AARTIDRUGS.BO trades at ₹347.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas AARTIDRUGS.BO's P/E ratio is 14.44. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to AARTIDRUGS.BO's ROE of +0.15%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to AARTIDRUGS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check AARTIDRUGS.BO's competition here
INDSWFTLTD.BO vs GUFICBIO.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, GUFICBIO.BO has a market cap of 27.5B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while GUFICBIO.BO trades at ₹290.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas GUFICBIO.BO's P/E ratio is 55.13. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to GUFICBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check GUFICBIO.BO's competition here
INDSWFTLTD.BO vs GUFICBIO.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, GUFICBIO.NS has a market cap of 27.5B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while GUFICBIO.NS trades at ₹288.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas GUFICBIO.NS's P/E ratio is 54.87. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to GUFICBIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check GUFICBIO.NS's competition here
INDSWFTLTD.BO vs GUJTHEM.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, GUJTHEM.NS has a market cap of 24.7B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while GUJTHEM.NS trades at ₹247.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas GUJTHEM.NS's P/E ratio is 51.80. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to GUJTHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check GUJTHEM.NS's competition here
INDSWFTLTD.BO vs ORCHPHARMA.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, ORCHPHARMA.NS has a market cap of 24.5B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while ORCHPHARMA.NS trades at ₹519.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas ORCHPHARMA.NS's P/E ratio is 128.31. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to ORCHPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check ORCHPHARMA.NS's competition here
INDSWFTLTD.BO vs ORCHPHARMA.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, ORCHPHARMA.BO has a market cap of 24.3B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while ORCHPHARMA.BO trades at ₹517.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas ORCHPHARMA.BO's P/E ratio is 126.55. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to ORCHPHARMA.BO's ROE of +0.00%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to ORCHPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check ORCHPHARMA.BO's competition here
INDSWFTLTD.BO vs NOVARTIND.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, NOVARTIND.BO has a market cap of 24B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while NOVARTIND.BO trades at ₹1,014.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas NOVARTIND.BO's P/E ratio is 24.63. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to NOVARTIND.BO's ROE of +0.13%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to NOVARTIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check NOVARTIND.BO's competition here
INDSWFTLTD.BO vs BLISSGVS.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, BLISSGVS.NS has a market cap of 22.8B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while BLISSGVS.NS trades at ₹229.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas BLISSGVS.NS's P/E ratio is 21.18. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to BLISSGVS.NS's ROE of +0.10%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to BLISSGVS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check BLISSGVS.NS's competition here
INDSWFTLTD.BO vs BLISSGVS.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, BLISSGVS.BO has a market cap of 22.8B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while BLISSGVS.BO trades at ₹229.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas BLISSGVS.BO's P/E ratio is 21.15. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to BLISSGVS.BO's ROE of +0.10%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to BLISSGVS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check BLISSGVS.BO's competition here
INDSWFTLTD.BO vs IOLCP.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, IOLCP.NS has a market cap of 21.4B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while IOLCP.NS trades at ₹77.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas IOLCP.NS's P/E ratio is 18.42. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to IOLCP.NS's ROE of +0.07%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to IOLCP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check IOLCP.NS's competition here
INDSWFTLTD.BO vs IOLCP.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, IOLCP.BO has a market cap of 21.4B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while IOLCP.BO trades at ₹77.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas IOLCP.BO's P/E ratio is 18.42. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to IOLCP.BO's ROE of +0.07%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to IOLCP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check IOLCP.BO's competition here
INDSWFTLTD.BO vs UNICHEMLAB.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, UNICHEMLAB.BO has a market cap of 20.7B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while UNICHEMLAB.BO trades at ₹299.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas UNICHEMLAB.BO's P/E ratio is 7.03. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to UNICHEMLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check UNICHEMLAB.BO's competition here
INDSWFTLTD.BO vs UNICHEMLAB.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, UNICHEMLAB.NS has a market cap of 20.7B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while UNICHEMLAB.NS trades at ₹298.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas UNICHEMLAB.NS's P/E ratio is 7.02. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to UNICHEMLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check UNICHEMLAB.NS's competition here
INDSWFTLTD.BO vs SOLARA.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, SOLARA.NS has a market cap of 20.5B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while SOLARA.NS trades at ₹459.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas SOLARA.NS's P/E ratio is -88.11. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to SOLARA.NS's ROE of -0.02%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to SOLARA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check SOLARA.NS's competition here
INDSWFTLTD.BO vs SOLARA.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, SOLARA.BO has a market cap of 20.5B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while SOLARA.BO trades at ₹460.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas SOLARA.BO's P/E ratio is -88.55. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to SOLARA.BO's ROE of -0.02%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to SOLARA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check SOLARA.BO's competition here
INDSWFTLTD.BO vs MOREPENLAB.BO Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, MOREPENLAB.BO has a market cap of 18.5B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while MOREPENLAB.BO trades at ₹37.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas MOREPENLAB.BO's P/E ratio is 18.88. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to MOREPENLAB.BO's ROE of +0.09%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to MOREPENLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check MOREPENLAB.BO's competition here
INDSWFTLTD.BO vs MOREPENLAB.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, MOREPENLAB.NS has a market cap of 18.5B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while MOREPENLAB.NS trades at ₹37.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas MOREPENLAB.NS's P/E ratio is 18.71. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to MOREPENLAB.NS's ROE of +0.09%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to MOREPENLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check MOREPENLAB.NS's competition here
INDSWFTLTD.BO vs ALEMBICLTD.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, ALEMBICLTD.NS has a market cap of 18.2B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while ALEMBICLTD.NS trades at ₹76.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas ALEMBICLTD.NS's P/E ratio is 5.71. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to ALEMBICLTD.NS's ROE of +0.13%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to ALEMBICLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check ALEMBICLTD.NS's competition here
INDSWFTLTD.BO vs HIKAL.NS Comparison April 2026
INDSWFTLTD.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INDSWFTLTD.BO stands at 850.4M. In comparison, HIKAL.NS has a market cap of 18.1B. Regarding current trading prices, INDSWFTLTD.BO is priced at ₹15.70, while HIKAL.NS trades at ₹159.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INDSWFTLTD.BO currently has a P/E ratio of 0.30, whereas HIKAL.NS's P/E ratio is -138.75. In terms of profitability, INDSWFTLTD.BO's ROE is -0.45%, compared to HIKAL.NS's ROE of -0.01%. Regarding short-term risk, INDSWFTLTD.BO is more volatile compared to HIKAL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for INDSWFTLTD.BO.Check HIKAL.NS's competition here